Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia

(2016) F. Nadeu et al.   BLOOD

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

(2016) C. D. Herling et al.   BLOOD

A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia

(2016) N. A. Amin et al.   CLINICAL CANCER RESEARCH

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation

(2016) Lijian Yu et al.   CLINICAL CANCER RESEARCH

Clinical impact of small subclones harboring NOTCH1 , SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia

(2016) Silvia Rasi et al.   HAEMATOLOGICA

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

(2016)   LANCET ONCOLOGY

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

(2016) E Young et al.   LEUKEMIA

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease

(2016) M J J Rose-Zerilli et al.   LEUKEMIA

Clinical impact of small subclones harboring NOTCH1 , SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia

(2016) Silvia Rasi et al.   HAEMATOLOGICA

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

(2015) V. Ljungstrom et al.   BLOOD

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

(2015) Philip A. Thompson et al.   CANCER

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia

(2015) Larry Mansouri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Non-coding recurrent mutations in chronic lymphocytic leukaemia

(2015) Xose S. Puente et al.   NATURE

Mutations driving CLL and their evolution in progression and relapse

(2015) Dan A. Landau et al.   NATURE

Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia

(2014) J. Ojha et al.   BLOOD

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia

(2014) D. Rossi et al.   BLOOD

Survival analysis in hematologic malignancies: recommendations for clinicians

(2014) J. Delgado et al.   HAEMATOLOGICA

Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption

(2014) J. Delgado et al.   HAEMATOLOGICA

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia

(2014) J Malcikova et al.   LEUKEMIA

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

(2014) P Baliakas et al.   LEUKEMIA

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia

(2013) Alexander Jethwa et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

Clonal evolution in hematological malignancies and therapeutic implications

(2013) D A Landau et al.   LEUKEMIA

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

(2013) S Jeromin et al.   LEUKEMIA

Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns

(2012) A. Schuh et al.   BLOOD

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial

(2012) Anna Skowronska et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia

(2011) P. Ouillette et al.   BLOOD

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

(2011) Lili Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD